Publications


Appraisal-specific

E Poku, J Rathbone, R Wong, E Everson-Hock, M Essat, A Pandor, A Wailoo. The safety of intravitreal bevacizumab monotherpay in adult ophthalmic conditions: systematic review. 2014 BMJ Open 4:e005244 doi:10.1136/bmjopen-2014-005244

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; Vol 47 (10): 1590

A Wailoo, N Bansback, J Chilcott. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance Rheumatology 2008; Vol 47 (2): 119-120

A Wailoo, A Sutton, A Morgan. The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009British Journal of Cancer Vol 100: 436-441

S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.


Methods development

Grimm, S.E., Strong, M., Brennan, A. et al. Framework for analysing risk in Health Technology Assessments and its application to Managed Entry Agreements (January 2016)

Grimm, S.E., Strong, M., Brennan, A. et al. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. PharmacoEconomics (2017) 35: 1287

M Hernández Alava, A Wailoo. ALDVMM: A command for fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. The Stata Journal 2015 In press. Available online.

B Pennington, S Davis. Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health 17(8):762-771 Dec 2014

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: a stated preference discrete choice experiment. Social Science & Medicine 2015; 124:48-56 (first published online November 2014)

M Hernández Alava, A Wailoo, F Wolfe, K Michaud. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Medical Decision Making 2014; 34:919-930 (first published online 2013 doi:10.1177/0272989X13500720)

O Ciani, S Davis, P Tappenden, R Garside, K Stein, A Cantrell, E D Saad, M Buse, R S Taylor Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers International Journal of Technology Assessment in Health Care 2014; 30 (3): 312-324

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: an empirical study of public preferences. European Journal of Health Economics 2014; 15 (4):389-399 (first published online May 2013; DOI 10.1007/s10198-013-0482-3)

B Kearns, R Ara, A Wailoo, A Manca, M Hernandez Alava, K Abrams, M Campbell. Good practice guidelines for the use of statistical regression models in economic evaluations. PharmacoEconomics (2013); 31 (8): 643-652

Thokala P, Duenas A The applicability of Multi Criteria Decision Analysis for Health Technology Assessment. Value in Health 2012; 15(8): 1172-1181

S Davis, A Wailoo. A review of the psychometric performance of the EQ-5D in people with urinary incontinence. Health and Quality of Life Outcomes 2013; 11 (20)

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: an exploratory preference elicitation study. HEDS Discussion Paper 11/17

J Morden, P Lambert, N Latimer, K Abrams, A Wailoo. Assessing methods for dealing with treatment switching in randomised clinical trials: A simulation study BMC Medical Research Methodology 2011; Vol 11:4

A Wailoo, A Tsuchiya, C McCabe. Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected. Pharmacoeconomics 2009; Vol 27 (12): 983-989

A Wailoo, A Sutton, N Cooper, D Turner, K Abrams, A Brennan, K Nicholson. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value in Health 2008; Vol 11 (2): 160-171.


Technical Support Documents

Evidence synthesis

S Dias, N Welton, A Sutton, A Ades. Evidence Synthesis for Decision Making 1: Introduction Med Decis Making July 2013 33: 597-606, doi:10.1177/0272989X13487604

S Dias, A Sutton, A Ades, N Welton. Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials Med Decis Making July 2013 33: 607-617, first published on October 26, 2012 doi:10.1177/0272989X12458724

S Dias, A Sutton, N Welton, A Ades. Evidence Synthesis for Decision Making 3: Heterogeneity-Subgroups, Meta-Regression, Bias, and Bias-Adjustment Med Decis Making July 2013 33: 618-640, doi:10.1177/0272989X13485157

S Dias, N Welton, A Sutton, D Caldwell, G Lu, A Ades Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials Med Decis MakingJuly 2013 33:641-656, doi:10.1177/0272989X12455847

S Dias, N Welton, A Sutton, A Ades. Evidence Synthesis for Decision Making 5: The Baseline Natural History Model Med Decis MakingJuly 2013 33:657-670, doi:10.1177/0272989X13485155

S Dias, A Sutton, N Welton, A Ades. Evidence Synthesis for Decision Making 6: Embedding Evidence Synthesis in Probabilistic Cost-effectiveness Analysis Med Decis MakingJuly 2013 33: 671-678, doi:10.1177/0272989X13487257

A Ades, D Caldwell, S Reken, N Welton, A Sutton, S Dias. Evidence Synthesis for Decision Making 7: A Reviewer’s Checklist Med Decis Making July 2013 33:679-691, doi:10.1177/0272989X13485156

Utilities

Papaioannou, J Brazier, S Paisley. Systematic searching and selection of health state utility values from the literature. Value in Health (2013); 16 (4): 686-695

L Longworth, D Rowen. Mapping to obtain EQ-5D utility values for use in NICE Health Technology Appraisals. Value in Health (2013); 16 (1): 202-210

R Ara, A Wailoo. Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies. Value in Health (2012) 15: 6.

Survival analysis

N. Latimer. Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Inconsistencies, limitations, and a practical guide. Medical Decision Making (2013) 33 (6): 743-754

A. Bagust, S. Beale. Survival analysis and extrapolation modeling of time-to-event clinical trail data for economic evaluation: an alternative approach. Medical Decision Making 2013; doi: 10.1177/0272989X13497998

N. Latimer. Response to “Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach” by Bagust and Beal. Medical Decision Making 2013; doi: 10.1177/0272989X13511302


Methods Guide update process 2008

Miners, A.(2008) Estimating ‘costs’ for cost-effectiveness analysis. Pharmacoeconomics Vol:26(9):745-751

Sutton, A.,Ades, AE.,Cooper, N.,Abrams, K.(2008) Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics Vol:26 (9): 753-767

Sculpher, M.(2008) Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics Vol: 26 (9): 799-806

McCabe,C.,Claxton,K.,Culyer, AJ.(2008) The NICE cost-effectiveness threshold. What it is and what that means. Pharmacoeconomics Vol: 26 (9): 733-744

Claxton, K.(2008) Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics Vol: 26: 781-798

Brazier, J.(2008) Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics Vol: 26 (9): 769-779